Abstract: The inputted character candidate display section (1213)/inputted character string candidate display section (1214) cause candidates of a character/character string, which is predicted as an intended character/character string to be inputted by the user, to be displayed as inputted character candidates/inputted character string candidate, and the converted character string candidate display section (1215) causes converted character string candidates, which have been obtained by converting the inputted character string candidate, to be displayed.
Abstract: A speech server (SS) managing one or a plurality of pieces of speech terminal-specifying information (STSI) and user-specifying information (USI), each of pieces of STSI allowing a corresponding one of one or a plurality of speech terminals to be specified, USI being of a user who is capable of causing the corresponding one of the one or a plurality of speech terminals to output speech. The SS receives USI and transmit the one or a plurality of pieces of STSI associated with USI. The SS receives (i) STSI selected from the one or a plurality of pieces of STSI transmitted and (ii) speech information indicative of speech content to be outputted as speech. The SS instructs a speech terminal to output the speech content as speech, the speech terminal being identified among the one or a plurality of speech terminals by STSI received.
Abstract: In a method of operating an optical sensor circuit (11) in accordance with one embodiment of the present invention, main reset is performed prior to sensing of incident light with use of a PIN diode (4) and, between the main reset and next main reset, auxiliary reset is performed so that a potential of a cathode terminal of the PIN diode (4) is reduced within a predetermined range within which storage of carriers is not induced in an intrinsic region of the PIN diode (4).
Abstract: In its many embodiments, the present invention provides certain C2-ring-substituted thiadiazine compounds, including compounds Formula (I): (structure represented) or tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R4, ring A, RA, m, -L1-, RL, and ring C are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
November 8, 2016
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jared N. Cumming, David Earl Kaelin, Jr., Jack D. Scott, Andrew W. Stamford, Ulrich Iserloh
Abstract: Disclosed is a photovoltaic device 1 including a plurality of cluster power generation sections G (G11, G12, G21, and G22). Each cluster power generation section G includes unitary power generation sections D (D1, D2) connected in series via connection points CP12. The cluster power generation sections G each have at least a predetermined one of the connection points CP12 designated as a specific connection point SP12. The specific connection points SP12 are connected together to link the cluster power generation sections G.
Abstract: Technique for initialization of encoders and decoders. In some cases, the decoder receives a slice and identifies if the slice is either a forward predicted B-slice or a backward predicted B-slice, and not both a forward and backward predicted B-slice, and based upon this identification initializes, using a P-slice technique, a context associated with the slice.
Abstract: A Channel State Information (CSI) feedback method and a User Equipment (UE) are provided for better support of Joint Transmission (JT) and Beamforming/Coordinated Scheduling (CB/CS). For JT, phase information for an adjacent Base Station (BS) is fed back. For CB/CS, enhanced CSI for an adjacent BS is fed back. The UE according to the present invention includes: a coordinated BS set determining unit configured for determining a set of coordinated BSs participating in multi-BS coordination, the set of coordinated BSs containing a serving BS and at least one non-serving BS; and a CSI feedback unit configured for feeding back CSI for JT or CB/CS for each non-serving BS in the set of coordinated BSs. The present invention has the advantages of simple implementation and low overhead and is applicable in LTE-A and 4G systems.
Type:
Grant
Filed:
May 23, 2012
Date of Patent:
November 8, 2016
Assignee:
Sharp Kabushiki Kaisha
Inventors:
Ming Ding, Lei Huang, Zeng Yang, Yuan Luo
Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.
Type:
Grant
Filed:
September 29, 2014
Date of Patent:
November 8, 2016
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Kenneth Jay Barr, Mark E. Scott, Christopher F. Thompson, Neville Anthony, Carolyn Michele Cammarano, Raman Kumar Bakshi, Subhendu Kumar Mohanty, Chandra Sekhar Korapala, Prashant R. Latthe, Vyjayanthi N. Kambam, Sujit Kumar Sarkar, Jayanth Thiruvellore Thatai
Abstract: The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R11 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
Type:
Application
Filed:
December 17, 2014
Publication date:
November 3, 2016
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
Thomas H. Graham, Wensheng Liu, Tao Yu, Yonglian Zhang, Sherman T. Waddell, John S. Wai, Paul J. Coleman, John M. Sanders, Mark W. Embrey, Abbas M. Walji, Ronald Dale Ferguson, II, Christine Ng Di Marco, Thomas G. Steele, Lihong Hu, Xuanjia Peng
Abstract: A field sequential processing unit 11 includes a representative value calculating unit 111 configured to obtain a representative value for each pixel based on video data Ri, Gi, and Bi, a backlight data generating unit 112 configured to generate backlight data Xb indicating brightness of LEDs 18 in each area of the backlight 17 based on the obtained representative value, a video data correcting unit 113 configured to correct the video data Ri, Gi, and Bi based on the backlight data Xb, and a field data generating unit 114 configured to generate four pieces of field data Wf, Rf, Gf, and Bf based on the corrected video data Rc, Gc, Bc. By generating the backlight data based on the representative value for each pixel, it is possible to reduce a size of a circuit for obtaining brightness of the backlight for each area.
Abstract: The invention disclosed herein is a novel media milling process performed in an atmosphere of propellants(s) utilizing a resonant acoustic mixing (RAM) device. The process is utilized to reduce the particle size of API (optionally including excipients) to a respirable size range while ensuring the retention of the crystallinity of the milled API.
Type:
Application
Filed:
December 12, 2014
Publication date:
November 3, 2016
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
BALAJI BHARATWAJ, SAI PRASANTH CHAMARTHY, CHINEDU G. OREKIE, YOEN-JU SON
Abstract: Residual prediction poses a problem that deriving a residual involves a large amount of processing for generating two motion-compensated images and deriving a difference. Provided is a residual prediction device including a reference image interpolation unit that derives two residual prediction motion-compensated images, and a residual synthesis unit that derives a residual from a difference between the two residual prediction motion-compensated images and derives a predicted image by adding the residual to a motion-compensated image, in which the residual synthesis unit derives a predicted image by adding the residual to the motion-compensated image in a case where a target block size is greater than a predetermined size and derives the motion-compensated image as the predicted image in a case where the target block size is less than or equal to a predetermined size.
Abstract: The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Abstract: The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Abstract: The present invention is directed to diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the diazepane compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Type:
Application
Filed:
December 16, 2014
Publication date:
November 3, 2016
Applicant:
MERCK SHARP & DOHME CORP.
Inventors:
SCOTT D. KUDUK, THOMAS S. REGER, ANTHONY J. ROECKER
Abstract: The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Abstract: Disclosed herein is a lipid nanoparticle (LNP) composition comprising (a) an Akt inhibitor; (b) DSPC; (c) cholesterol; and (d) PEG-DMG. Also disclosed herein is a method for preparing the lipid composition using a scalable tangential flow micro-mixing technology.
Abstract: An electronic device is provided to allow a user to take a selfie while the user looks directly at the camera. A smartphone includes: a monitor; a camera provided at a display surface side of the monitor; and a CPU configured to control the smartphone. The CPU includes a display control unit configured to display, during image capturing of a subject by the camera, an object in a first display area on the monitor in order to lead gaze of a user of the smartphone to the camera, the first display area being located within a predetermined range from a location of the camera of the smartphone.
Abstract: A semiconductor laser element is provided with: a substrate formed of a semiconductor; a semiconductor laminated film, which is laminated on the substrate, and which includes an active layer; a first electrode and a second electrode, which are provided on surfaces parallel to the active layer on the side where the semiconductor laminated film is formed on the substrate; and a facet protection film that is provided on both the facets, which are perpendicular to the active layer, and which face each other. In the semiconductor laser element, the facet is used as a fixing surface for the semiconductor laser element, said facet having the facet protection film formed thereon.
Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is (CH2) or O, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:
Type:
Application
Filed:
December 12, 2014
Publication date:
November 3, 2016
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Pengcheng Patrick SHAO, Feng YE, Petr VACHAL